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Background: Mutations in the gene encoding ryanodine receptor type-1 (RYR1), the calcium ion (Ca2+) release
channel in the sarcoplasmic reticulum (SR) of skeletal muscle, are linked to central core disease (CCD) and malignant
hyperthermia (MH) susceptibility. We recently reported that mice lacking the skeletal isoform of calsequestrin
(CASQ1-null), the primary Ca2+ buffer in the SR of skeletal muscle and a modulator of RYR1 activity, exhibit lethal
heat- and anesthetic-induced hypermetabolic episodes that resemble MH events in humans.
Methods: We compared ultrastructure, oxidative status, and contractile function in skeletal fibers of extensor
digitorum longus (EDL) muscles in wild type (WT) and CASQ1-null mice at different ages (from 4 to 27 months) using
structural, biochemical, and functional assays.
Results: About 25% of fibers in EDL muscles from CASQ1-null mice of 14 to 27 months of age exhibited large areas
of structural disarray (named core-like regions), which were rarely observed in muscle from age-matched WT mice.
To determine early events that may lead to the formation of cores, we analyzed EDL muscles from adult mice: at 4
to 6 months of age, CASQ1-null mice (compared to WT) displayed significantly reduced grip strength (40 ± 1 vs.
86 ± 1 mN/gr) and exhibited an increase in the percentage of damaged mitochondria (15.1% vs. 2.6%) and a
decrease in average cross-sectional fiber area (approximately 37%) in EDL fibers. Finally, oxidative stress was also
significantly increased (25% reduction in ratio between reduced and oxidized glutathione, or GSH/GSSG, and 35%
increase in production of mitochondrial superoxide flashes). Providing ad libitum access to N-acetylcysteine in the
drinking water for 2 months normalized GSH/GSSG ratio, reduced mitochondrial damage (down to 8.9%), and
improved grip strength (from 46 ± 3 to 59 ± 2 mN/gr) in CASQ1-null mice.
Conclusions: Our findings: 1) demonstrate that ablation of CASQ1 leads to enhanced oxidative stress, mitochondrial
damage, and the formation of structural cores in skeletal muscle; 2) provide new insights in the pathogenic mechanisms
that lead to damage/disappearance of mitochondria in cores; and 3) suggest that antioxidants may provide some
therapeutic benefit in reducing mitochondrial damage, limiting the development of cores, and improving muscle function.
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In skeletal muscle, excitation-contraction (EC) coupling
is a process by which depolarization of the transverse
(T)-tubule membrane is mechanically linked to the release
of calcium ions (Ca2+) from the sarcoplasmic reticulum
(SR) and, hence, activation of muscle contraction [1]. EC* Correspondence: fprotasi@unich.it
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communication between T-tubule voltage sensors (dihy-
dropyridine receptors, α1sDHPRs) and SR Ca
2+ release
channels (ryanodine receptor type-1, RYR1) [2,3]. Several
other junctional proteins, including calsequestrin-1, tria-
din, junctin, JP-45, stac3, and FK-506 binding protein,
interact with RYR1 and α1sDHPR to form a macromol-
ecular machinery that controls Ca2+ release [4]. Several
pathological conditions that adversely affect striated
muscle function are associated with mutations in ECticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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control of SR Ca2+ release [5].
Mutations in the RYR1 gene account for the majority
of cases of malignant hyperthermia susceptibility (MHS)
and central core disease (CCD) in humans [6-8]. CCD is
one of the most common congenital myopathies: CCD
patients exhibit fetal hypotonia, proximal muscle weak-
ness, and a significant delay in motor development
[9,10]. Diagnosis of CCD is confirmed by histological
examination of muscle biopsies showing amorphous
central areas (or cores, typically found in type I fibers)
lacking glycolytic/oxidative enzymes and mitochondria
[11]. Disorganization of the contractile elements and
sarco-tubular systems is typically observed within the
core regions [12]. MHS, on the other hand, is a pharma-
cogenetic disorder characterized by life-threatening epi-
sodes triggered by volatile anesthetics (for example,
halothane, isoflurane, etc.) and depolarizing muscle re-
laxants (for example, succinylcholine) [13-15] that oc-
curs in the absence of an overt myopathy. CCD and
MHS are often related: some patients with CCD test
positive for MHS [16,10] and, thus, are considered at
risk for malignant hyperthermia (MH) [17].
Calsequestrin (CASQ) is a highly acidic protein that
binds Ca2+ that is concentrated at the junctional face of
the terminal cisternae, near the sites of RYR1 Ca2+ release
[18-20]. There are two isoforms of mammalian CASQ that
are products of different genes: the skeletal (CASQ1) and
cardiac (CASQ2) isoforms, which are expressed at differ-
ent levels during development of fast- and slow-twitch
skeletal muscle fibers [21,22]. In addition to being import-
ant for SR Ca2+ binding/storage, CASQ1 also modulates
the RYR1 Ca2+ release channel activity [23,24].
Our structural and functional studies in CASQ1-
knockout (or null) mice revealed that while CASQ1
ablation is not lethal [25], skeletal muscle from CASQ1-
null mice exhibits significant structural remodeling of
Ca2+ release units (CRUs) and impaired Ca2+ handling
[25-27]. Abnormal CRUs (that is, forming multiple ele-
ments with reduced junctional SR lumen) exhibit rapid
and severe SR Ca2+ depletion in response to repetitive
stimulation [28]. As a result, EC coupling is unable to
support prolonged Ca2+ transients required to sustain
force production during tetanic stimulation [26,28]. Im-
portantly, CASQ1-null mice also exhibit life-threatening,
hypermetabolic episodes characterized by sustained mus-
cle contractures, rhabdomyolysis, and uncontrolled eleva-
tions in core body temperature when exposed to either
halothane or environmental heat stress [29-31], which
closely resemble human MHS [14,15]. However, muta-
tions in the CASQ1 gene have not been identified in MH
patients. In fact, Kraeva et al. [32] failed to identify any
mutations within the CASQ1 coding region in 75 un-
related MHS patients diagnosed by caffeine-halothanecontracture test, thus concluding that CASQ1 is an un-
likely genetic locus for MHS within the North American
population [33]. A similar conclusion was reached in
another study of European MHS patients (Vincenzo
Sorrentino, University of Siena, personal communica-
tion). However, a missense mutation in the CASQ1 gene
(N244G, the first CASQ1 disease mutation identified in
humans) was recently reported in a group of patients
with a myopathy characterized by weakness, fatigue, and
the presence of large vacuoles containing characteristic
inclusions resulting from the aggregation of SR proteins
[34]. The MH status of individuals that possess the
N244G mutation in CASQ1 is currently unknown.
Since CASQ1 exhibits an MHS-like phenotype and
MHS occurs in some CCD patients, we hypothesized
that CASQ1-null mice may develop a myopathy resem-
bling CCD. To test this hypothesis, we compared
skeletal muscle ultrastructure, oxidative status, and con-
tractile function in wild type (WT) and CASQ1-null
mice at different ages (4 to 6, 14, 20, 24, and 27 months).
Our results indicate that CASQ1-null mice exhibit im-
paired muscle function (that is, reduced force output),
mitochondrial damage, and structural core-like regions
similar to that described previously in RYR1 mouse
models of MH/CCD [35,36]. We found that increased
oxidative stress appears to be a key trigger for this myo-
pathic phenotype in CASQ1-null mice as treatment with
the antioxidant N-acetylcysteine (NAC) provides signifi-
cant protection from the development of structural and
functional deficits.
Methods
All functional, structural, and molecular analyses were
carried out in either a) extensor digitorum longus (EDL;
predominantly fast-twitch fibers), the muscle group
which is more affected by CASQ1 ablation [25,26], or b)
flexor digitorum brevis (FDB; approximately 80% of fast-
twitch fibers; [37]) for single cell experiments.
Ethics statement
All experiments were conducted according to the Dir-
ective of the European Union 2010/63/UE and the Na-
tional Institutes of Health Guide for the Care and Use of
Laboratory Animals. All animal protocols were approved
by the Committee on the Ethics of Animal Experiments
of the University of Chieti (CEISA; Permit Number: 40)
and the University Committee on Animal Resources at
the University of Rochester Medical Center. All surgeries
were made to minimize animal suffering: animals were
anesthetized and then sacrificed by cervical dislocation.
CASQ1-null mice
CASQ1-null mice [25] were housed in micro-isolator
cages, at 20°C in a 12-h light/dark cycle, with free access
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male mice is significantly reduced (see Additional file 1:
Figure S1; see also refs. [29,31]), all experiments con-
ducted in this study were performed using female WT
and CASQ1-null animals (due to shortage of aged male
CASQ1-null mice). For in vivo antioxidant treatment,
mice were provided ad libitum access to drinking water
containing NAC (1% w/v).
Grip strength test
Grip strength of WT and CASQ1-null mice from three
different age groups (4 to 6, 14, and 22 to 24 months of
age) was measured as described by Connolly et al. [38].
Briefly, mice were held by the tail and lowered to a metal
grating connected to the shaft of a Shimpo Fgv 0.5X
force transducer (Metrotec Group, San Sebastián, Spain).
Once the mouse had firmly grabbed the grating, a gentle
pull was exerted on the tail. Measurements of peak force
generated by each mouse using fore and hind limbs were
repeated three times with appropriate intervals (at least
30 s) to avoid fatigue. Average peak force values were
normalized to total body mass measured immediately
before each experiment.
Force and contraction kinetics of isolated EDL muscles
EDL muscles were dissected from the hind limb of WT
and CASQ1-null mice of three different age groups (4 to
6, 14, and 22 to 24 months old). Force and contraction
kinetics were measured as described by Paolini et al.
[25]. Excised muscles were continuously perfused with
oxygenated Krebs solution (NaCl 118 mM, KCl 4.7 mM,
MgSO4 1.2 mM, KH2PO4 1.1 mM, glucose 11.1 mM,
CaCl2 2.5 mM, NaHCO3 25 mM, pH 7.4) and mounted
between a force transducer (AME-801 SensorOne,
Sausalito, CA, USA) and micromanipulator-controlled
shaft in a small chamber. The temperature of the
chamber was maintained at 25°C. The stimulation con-
ditions were optimized, and muscle length was in-
creased until force development during tetanus was
maximal. Single twitches and fused tetani (120 Hz, 0.5-
s duration) under isometric conditions were recorded
with rest intervals suitable to avoid fatigue. Specific
force (mN/mm2) and time to peak contraction (s) were
measured.
Preparation of samples for histology and EM
EDL muscles were carefully dissected from WT and
CASQ1-null mice at different ages (4 to 6, 14, 20, 24,
and 27 months). Muscles were fixed at room tem-
perature (RT) in 3.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer, pH 7.2, for 2 h and kept in fixative
until further use. Small bundles of fibers were then post-
fixed and embedded as described by Paolini et al. [25].
For histological analyses, longitudinal and cross-orientedsemithin sections (250 nm) were cut with a Leica Ultra-
cut R microtome (Leica Microsystem, Vienna, Austria)
using a Diatome diamond knife (Diatome Ltd. CH-
2501 Biel, Switzerland). After staining with toluidine
blue dye, the sections were viewed on a Leica DMLB
fluorescence microscope (Leica Microsystem, Vienna,
Austria). For electron microscopy (EM), ultrathin sec-
tions were cut (approximately 50 nm), stained in 4%
uranyl acetate and lead citrate, and examined with a
Morgagni Series 268D electron microscope (FEI Com-
pany, Brno, Czech Republic) equipped with a Megaview
III digital camera.
Quantitative analyses of histological and EM specimens
1) Measurements of fiber cross-sectional area (CSA)
were performed on cross-oriented semithin sections of
EDL muscles from WT and CASQ1-null mice of 4 to 6,
14, and 24 months of age (by histological analysis).
Images were selected and CSA calculated using the Analy-
SIS software (Olympus Soft Imaging Solutions GmbH,
Munster, Germany). 2) Mitochondrial volume was deter-
mined in adult (4 to 6 months) and aged (27 months) WT
and CASQ1-null mice before and after NAC treatment.
Mitochondrial volume was calculated using the well-
established stereology point-counting technique [39,40] in
EM micrographs taken at 14,000× of magnification after
superimposing an orthogonal array of dots at a spacing of
0.20 μm to the electron micrographs. The ratio between
the number of dots falling within the mitochondrial pro-
file and the total number of dots covering the whole image
was used to calculate the relative volume of the fiber
occupied by mitochondria. 3) The number of altered
mitochondria was determined in EDL muscles from 4-
to 6-month-old WT and CASQ1-null mice (in the ab-
sence or presence of NAC treatment) using the same
set of EM micrographs as described for the mitochon-
drial volume measurements. Mitochondria with any one
(or more) of the following ultrastructural alterations
were classified as damaged: a) swollen mitochondria, b)
mitochondria with clear disruption of the external
membrane and/or internal cristae, c) mitochondria con-
taining vacuoles, and d) mitochondria containing myelin
figures. The quantification was reported as the percentage
of all mitochondria evaluated in the fiber. 4) Determin-
ation of the number of damaged fibers in adult (4-month-
old) and aged (four time points between 14 and 27
months of age) mice was performed on histological sec-
tions stained with toluidine blue. Quantitative analysis was
performed at multiple time points for each genotype. Indi-
vidual fibers were visually scored for the presence of un-
structured cores and contracture cores, as described in
Boncompagni et al. 2009 [35]. The number of fibers with
alterations was presented as a percentage of all fibers
evaluated.
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Dissected EDL muscles from 27-month-old WT and
CASQ1-null mice were fixed in 2% paraformaldehyde in
phosphate-buffered saline (PBS) for 20 min at RT. Small
bundles of fibers were blocked for 1 h in PBS containing
1% bovine serum albumin (BSA), 10% goat serum, and
0.5% TRITON X-100 and then incubated overnight at 4°C
with primary antibodies. After washing in PBS/BSA, fibers
were incubated for 1 h at RT with secondary antibodies,
washed again, and finally mounted with an anti-bleach
medium. Code, specificity, working dilution, and the
sources of primary and secondary antibodies used were as
follows: mouse anti-RYR 34C, 1:30 [41] (Developmental
Studies Hybridoma Bank, The University of Iowa), and
Cy3 goat anti-mouse, 1:200 (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA). The specimens were
viewed using a laser-scanning confocal microscope inter-
faced with an inverted Zeiss Axiovert microscope (LSM510
META, Zeiss, Germany).
Gene profile analyses
Microarray analyses were performed by CRIBI - Biotech-
nology Center and Biology Department Padua University -
using spotted oligonucleotide Micro-CRIBI Mouse Oligo
13.4k Array V_0 (Operon Version 1.1), GEO accession
platform number GPL6747. This microarray set consists
of 13.440 70-mer oligonucleotides designed on Mouse
Unigene clusters, mainly in the 3′ end terminal region.
Briefly, each oligonucleotide is spotted by a robotic station
Biorobotics Microgrid II, in one replicate on a MICRO-
MAX glass slide SuperChip I (Cat No MPS696) provided
by PerkinElmer Life Sciences Inc. The deposition is quali-
tatively assessed by a scan of the spotted slide at 10-μm
resolution, using a ScanArray LITE (PerkinElmer, Waltham,
MA, USA). Code GSE25984 at: http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?token=xdojfeeesguuwji&acc=GSE
25984.
For all genes, P = 0.05, −0,65 > LogR > 0,65.
Western blot analysis
Preparation of total homogenates from EDL muscles of
4-month-old female WT and CASQ1-null mice were
performed as previously described [25]. Identification of
peroxisome proliferator-activated receptor gamma coac-
tivator 1-alpha (PGC-1α) was obtained in three different
EDL muscles from three different animals using a poly-
clonal antibody (H-300 Santa Cruz Biotechnology,
Dallas, TX, USA) diluted at 1:200. Immuno-detection was
performed using an anti-rabbit alkaline phosphatase-
conjugated antibody at a 1:10.000 dilution. For densito-
metric analysis, scans of nitrocellulose membranes were
quantified using Scion Image J Software (National Insti-
tutes of Health, Bethesda, MD, USA). Normalization to
actin was performed using Ponceau S red staining toassess total protein loading (100 μg per lane). Mean op-
tical density (O.D.) values of PGC-1α bands were normal-
ized to that observed for WT muscles, set as 100 O.D.,
and data were presented as density ratio. As the PGC-1α
antibody detected a doublet in all samples, the two bands
were compared with that of a positive control (A-673 nu-
clear extract from rhabdomyosarcoma cells, Santa Cruz
Biotechnology, Dallas, TX, USA) to determine the band
corresponding to PGC-1α: PGC-1α was identified as the
lower band in the doublet observed upon Western blot
analysis (see Additional file 2: Figure S2).
In vivo electroporation of mt-cpYFP cDNA into hind limb
footpads of anesthetized mice
WT and CASQ1-null mice (4 to 5 months old) were
anesthetized by intraperitoneal injection of 100 mg/kg
ketamine, 10 mg/kg xylazine, and 3 mg/kg aceproma-
zine. Hind limb footpads of anesthetized mice were then
injected subcutaneously with bovine hyaluronidase (7 μl/
foot, 2 μg/μl). One hour later, hind limb footpads were
subcutaneously injected with 30 μg of mitochondria-
targeted circularly permuted yellow fluorescent protein
(mt-cpYFP) cDNA (total volume 10 μl in 71 mM NaCl)
using a 30-gauge needle. The footpad was then electropo-
rated (100 V/cm, 20-ms duration, 20 pulses delivered at 1
Hz) using subcutaneous gold-plated electrodes placed per-
pendicular to the long axis of the muscle. Individual FDB
fibers were isolated by enzymatic dissociation 1 week after
electroporation as described previously [42].
mSOF measurement and analyses
Acutely isolated FDB fibers (from n = 4 to 5 mice) were
plated on glass-bottom dishes in a rodent Ringer’s solu-
tion (146 mM NaCl, 5 mM KCl, 1 mM MgCl, 2 mM
CaCl2, 10 mM HEPES, pH 7.4) and then loaded with 10
nM tetramethylrhodamine ethyl ester (TMRE) to enable
simultaneous monitoring of changes in mitochondrial
membrane potential during mitoflash activity. Mt-cpYFP
and TMRE were excited using 488-nm (8× attenuation)
and 543-nm (64× attenuation) lasers and detected at
515/30-nm and 605/75-nm emission, respectively. Time-
lapse x,y images were acquired at 1.24 s/frame and
512 × 512 resolution, with a total of 100 frames, using a
Nikon Eclipse C1 Plus Confocal microscope equipped
with a SuperFluor 60x (1.4 NA) oil-immersion objective.
Automated detection and analysis of individual mito-
chondrial superoxide flash (mSOF) events during time-
lapse x,y imaging was performed using ‘Flash Collector,’
a MATLAB-based image analysis program described in
detail previously [42]. Flash frequency, amplitude, and
full duration at half maximal amplitude (FDHM) were
expressed as the number of events/1,000 μm2∙100 s, ΔF/
F0, and seconds, respectively. Output data from Flash
Collector were tabulated, averaged, and evaluated for
Figure 1 EDL muscles from CASQ1-null mice exhibit impaired force
output and slowed kinetics of contraction. (A) Maximal grip strength
(normalized to body weight) is significantly reduced across all ages
in CASQ1-null mice compared to WT. (B) Peak-specific force measured
during maximal fused isometric tetanic contractions in excised EDL
muscles is significantly reduced in 14- and 22- to 24-month-old
CASQ1-null mice compared to WT and in CASQ1-null mice from 4 to
6 months to 14 months of age. (C) Time-to-peak isometric twitch
force is significantly increased in CASQ1-null mice across all ages
compared to WT and increases both in WT and CASQ1-null mice
up to 22 to 24 months. Number of animals tested for grip strength
test: WT, n = 175, 31, and 9 for 4 to 6, 14, and 22 to 24 months of
age, respectively; CASQ1-null, n = 157, 51, and 9 for 4 to 6, 14, and
22 to 24 months of age, respectively. Number of animals tested for
force and contraction kinetics: WT, n = 5, 8, and 10 for 4 to 6, 14,
and 22 to 24 months of age, respectively; CASQ1-null, n = 5, 5, and 6
for 4 to 6, 14, and 22 to 24 months of age, respectively. Data are given
as means ± SEM (*P < 0.05, **P < 0.01). EDL, extensor digitorum brevis;
CASQ1, skeletal isoform of calsequestrin; WT, wild type.
Paolini et al. Skeletal Muscle  (2015) 5:10 Page 5 of 17statistical significance using Microsoft Excel and Sigma-
Plot software suites.
Glutathione assay
Control and NAC-treated (for 2 months) 4-month-old
WT and CASQ1-null mice were sacrificed and hind limb
muscles removed. Hind limb muscles were homoge-
nized, and total glutathione and oxidized glutathione
(GSSG) levels were measured according to [43]. Briefly,
0.1 g of tissue sample was homogenized in 1 ml of fresh
extraction buffer (0.1% Triton X-100 and 0.6% sulfosa-
licylic acid in 0.1 M potassium phosphate buffer with 5
mM EDTA disodium salt, pH 7.5) on ice three times
using an MICCRA D-1 Homogenizer (ART Prozess- &
Labortechnik GmbH & Co., Müllheim, Germany). After
homogenization, 5% trichloroacetic acid was added to
the solution, and the homogenized tissue sample was
centrifuged at 8,000 × g for 10 min at 2°C to 4°C to ob-
tain a supernatant containing glutathione. The sample
was then stored at −80°C until further use. The assay
used for measurement of total glutathione and GSSG is
based on the reaction of reduced glutathione (GSH; dir-
ectly or through conversion of GSSG to GSH by 2-
vinylpyridine) with 5,5′-dithio-bis (2-nitrobenzoic acid)
(DTNB), which produces the 5-thio-2-nitrobenzene (TNB)
chromophore measured at 412 nm. The rate of TNB for-
mation (change in absorbance min−1) is proportional to
the concentration of GSH in the sample. The assay was
performed in 96 well plates (96 Well Tissue Culture Test-
plate; Spl Life Sciences, Gyeonggi-do, Korea) using an Ab-
sorbance Microplate Reader SpectraMAX 190 (Molecular
Devices, Sunnyvale, CA, USA). The GSH concentration in
each sample was determined by linear regression using a
standardized GSH curve. The GSH/GSSG ratio was then
calculated.
Statistical analyses
Statistical significance for measurements of cores in WT
and CASQ1-null mice was evaluated using a two-tailed
Fisher exact test. Two-tailed Student’s unpaired t test or
one-way ANOVA test was used for statistical analysis of
all other experiments as appropriate. In all cases, statis-
tical significance was set at either P < 0.05 (*) or P < 0.01
(**). Statistical analyses were performed using GraphPad
Prism 5 (GraphPad Software, San Diego, CA, USA). All
measurements were expressed as mean ± SEM.
Results
Due to the high mortality of CASQ1-null male mice, all
experiments in this study were conducted using female
WT and CASQ1-null animals. See the ‘CASQ1-null
mice’ subsection of the ‘Methods’ section and Additional
file 1: Figure S1 for additional details.EDL muscle from CASQ1-null mice exhibit decreased force
output and slowed kinetics of contraction
To determine the functional output of muscle from
CASQ1-null mice at different ages, we performed grip
strength measurements. CASQ1-null mice exhibited
significantly reduced normalized grip strength (mN/g)
compared to that of WT mice across all ages tested
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Interestingly, while grip strength in CASQ1-null mice
decreased significantly between 4 to 6 and 14 months,
the deficit remained stable from 14 months to 22 to 24
months. The central role of skeletal muscle in this
decrease in force output was confirmed by ex vivo
experiments in isolated EDL muscles (Figure 1B,C). Spe-
cifically, maximal tetanic-specific force (measured at op-
timal length at 120 Hz under isometric conditions) was
significantly (P < 0.05) reduced in CASQ1-null mice
compared to WT mice at both 14 and 22 to 24 months
of age, but not at 4 to 6 months of age (Figure 1B).
Again, as in the grip strength test above, peak tetanic
force significantly (P < 0.05) decreased in CASQ1-null
mice from 4 to 6 months to 14 months but remained
unchanged from 14 months to 22 to 24 months. Finally,
time-to-peak tetanic contraction was also significantly
increased in EDL muscles from CASQ1-null mice com-
pared to WT mice across all evaluated ages (Figure 1C;
P < 0.05 and P < 0.01). Time to peak in CASQ1-null
EDLs becomes progressively slower up to 22 to 24
months.
Formation of cores in EDL muscle fibers of CASQ1-null
mice
To provide insight into the reduced contractility of EDL
muscles from CASQ1-null mice (Figure 1), we used a
combination of light and electron microscopy (EM) to
compare the ultrastructure of muscle fibers of EDL mus-
cles from age-matched WT and CASQ1-null mice.
While significant structural modifications were rare at 4Figure 2 Structural abnormalities in EDL muscle fibers from aged CASQ1-nul
disarrangement of contractile elements. Nevertheless, even in these fibers, no
of myofibrils and frequent mitochondria exhibiting clear signs of structural da
in which Z lines ((B), small arrows) and contractile elements are out of registe
fibers from EDL muscle from CASQ1-null mice. Z-line streaming is also presen
excessive sarcomere shortening, contain fewer and severely damaged mitoch
quantitative analyses. Scale bars: (A, B), 1 μm; (C, D), 0.5 μm; insets, 0.1 μm. EDto 6 months of age, the percentage of EDL fibers from
CASQ1-null mice exhibiting extended areas of morpho-
logical alterations significantly increased from 4 to 6
months to 14 months and older (Figures 2, 3, and 4 and
Additional file 3: Table S1). At the EM level, the struc-
tural alterations observed in fibers from CASQ1-null
mice reflected a progression from modest to more se-
vere irregularities, often characterized by the presence of
swollen mitochondria (Figure 2A, arrowheads and inset)
and misalignment of contractile elements (Figure 2B, ar-
rows), some Z-line streaming (Figure 2C, empty arrows),
and formation of regions of myofibril contractures
(Figure 2D). Similar areas of disrupted cross-striations
and/or hyper-contracture were only very rarely observed
in EDL fibers of WT mice (Additional file 3: Table S1),
even at the most advanced age investigated (27 months).
Although structural alterations observed in muscle fi-
bers from CASQ1-null mice were variable in appear-
ance, we classified two primary forms of disarray
detectable by both light and electron microscopy: 1) ex-
tensive areas lacking regular cross-striation and order,
termed unstructured cores (Figure 2B,C; and Figure 3C,
stars), and 2) areas exhibiting extreme sarcomere shorten-
ing, termed contracture cores (Figure 2D; and Figure 3E,F,
empty arrows). This terminology was previously intro-
duced by Boncompagni et al. [35] in a mouse model car-
rying a mutation in RYR1 that results in MH with cores in
humans. Such alterations were also visible by immuno-
labeling with anti-RYR1 antibodies, which revealed a par-
tial disruption in the normally highly ordered double-row
pattern of CRU distribution within regions of unstructured
cores (compare Figure 3B,D, white boxes and insets).l mice. (A) Many fibers (even at 19 months of age) do not present severe
rmal muscle ultrastructure is not well preserved, with partial misalignment
mage/swelling (arrowheads, see also inset). (B, C) Unstructured cores, areas
r and sarcomeres are partially disarranged, are frequently observed in
t in some fibers ((C), empty arrows). (D) Contracture cores, areas of
ondria (inset). See Figure 1 and Additional file 3: Table S1 for detailed
L, extensor digitorum brevis; CASQ1, skeletal isoform of calsequestrin.
Figure 3 Unstructured and contracture cores in EDL muscle fibers from aged CASQ1-null mice. (A, C) Histological examination by light
microscopy of EDL muscle fibers at 27 months of age. While fibers from WT mice maintain a well-preserved cross-striation pattern (A), fibers
from CASQ1-null mice often exhibit regions of degeneration ((C), stars) classified as unstructured cores. (B, D) Immuno-fluorescence imaging
with anti-RYR1 antibody shows loss of the precise double-row cross-striations (visible in WT, inset in (B) in fibers from CASQ1-null mice (inset
in (D)). (E, F) Both histology (E) and electron microscopy (F) revealed the presence in some fibers of confined areas of contracture (empty
arrows), defined as contracture cores, which are frequent in fibers from CASQ1-null mice. See Figure 1 and Additional file 3: Table S1 for
detailed quantitative analyses. Scale bars: (A-E), 5 μm; (F), 1 μm; insets, 2 μm. EDL, extensor digitorum brevis; CASQ1, skeletal isoform of
calsequestrin; RYR, ryanodine receptor; WT, wild type.
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ther unstructured or contracture cores (Figure 4 and
Additional file 3: Table S1). While fibers with extended
structural alterations in CASQ1-null mice were found in
only 2% of fibers at 4 months of age, their frequency in-
creased significantly from 4 to 14 months of age (about
25%), with no further significant changes at older ages
(Figure 4 and Additional file 3: Table S1, column C).
However, these regions typically occupied only a limited
area at early ages (14 months old), becoming much more
extensive at older ages (20 to 27 months old). Fibers pre-
senting cores were very rare in WT muscle even at the
oldest age analyzed (only 8% at 27 months of age), and
areas of alteration were usually very confined. Statistical
analyses (Figure 4 and Additional file 3: Table S1) indi-
cate that the total percentage of fibers presenting alter-
ations in EDL muscles of CASQ1-null mice was
significantly higher than that observed in WT mice at
each of the time points analyzed except at 4 months
(Figure 4).
Reduced CSA of EDL muscle fibers from CASQ1-null mice
Female CASQ1-null mice exhibited a significant reduc-
tion (approximately 15%) in body weight across all agescompared to age-matched WT female mice (Additional
file 4: Table S2), similar to that reported previously for
adult male mice [25]. As average EDL dry weight and
muscle/body weight ratio were reduced approximately
20% to 30% in CASQ1-null mice across all ages
(Additional file 4: Table S2), the decrease in total body
weight is likely, or at least in part, due to the reduction
in muscle mass. Indeed, measurements of CSA of EDL
muscle fibers at three different ages (Figure 5) verified
that fiber size was significantly reduced in EDL muscles
from CASQ1-null mice compared to the age-matched
WT mice across all ages (P < 0.01). Average CSA de-
creased from 4 to 6 months to 24 months of age in both
genotypes (33.3% in CASQ1-null mice vs. 41.3% of WT fi-
bers). Interestingly, the major drop in CSA in fibers from
CASQ1-null mice occurred between 4 and 14 months of
age, with no further significant change observed from 14
to 24 months (Figure 5), a finding that parallels the
functional (Figure 1A,B) and structural (Figure 4 and
Additional file 3: Table S1) data. Microarray analyses of
EDL muscles from 4-month-old CASQ1-null mice re-
vealed a significant up-regulation of four atrogenes
(CathepsinL, Bnip3, Psmd1, and Atrogin1) that belong
to the autophagy and ubiquitin-proteasome pathways,
Figure 4 Increased incidence of unstructured and contracture cores in 14- to 27-month-old CASQ1-null mice. While the percentage of fibers in
WT mice exhibiting structural cores remained low across all ages (maximum of 8% at 27 months of age), muscle fibers from CASQ1-null mice
exhibited a significantly increased frequency (*P < 0.05) of structural cores from 4 months of age (approximately 2%) to 14 months (23%),
remaining approximately unchanged thereafter (see also Additional file 3: Table S1 for additional detail). CASQ1, skeletal isoform of calsequestrin;
WT, wild type.
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rophy observed in muscle fibers from CASQ1-null mice
(Additional file 5: Table S3).
Age-dependent increase in mitochondrial damage in EDL
muscle from CASQ1-null mice
Muscle fibers from young (4- to 6-month-old) CASQ1-
null mice do not exhibit structural cores (though
clearly visible at later stages (see Figures 2, 3, and 4
and Additional file 3: Table S1). However, structural
analyses at higher magnification with EM of muscle fi-
bers at this age revealed that a) the frequency of mito-
chondria in muscle fibers from CASQ1-null mice is
increased (Figure 6A,B, empty arrows), an observation
consistent with previous findings [25], and b) mito-
chondria exhibiting evidence of structural damage were
more frequently observed in muscle fibers from CASQ1-
null mice (Figure 6B, black arrows and Figure 6G).
We measured relative mitochondrial volume (expressed
as a percentage of total fiber volume) in EDL muscle from
4- to 6-month-old mice and confirmed a significant
increase (approximately 2.4-fold) in cellular mitochondrial
volume in muscle fibers from 4- to 6-month-old CASQ1-
null mice compared to age-matched WT mice (Figure 6C;
P < 0.01). As the transcriptional co-activator PGC-1α
regulates many aspects of oxidative metabolism [44], in-
cluding mitochondrial biogenesis and fiber-type switching
from glycolytic toward more oxidative fibers [45], we
quantified PGC-1α expression by Western blot analysis in
EDL muscle homogenates from 4-month-old WT and
CASQ1-null mice (Additional file 2: Figure S2). PGC-1α
levels (Additional file 2: Figure S2, panel A, lower bandpointed by the arrow) were increased almost twofold in
EDL muscle homogenates from adult CASQ1-null mice
(P < 0.01). This significant increase in PGC-1α suggests
that the observed increase in mitochondrial volume in
muscle from CASQ1-null mice is due in part from in-
creased mitochondrial biogenesis. In addition, consistent
with increased oxidative fiber content (including increased
capillarization, as well as mitochondrial, myoglobin, and
heme content), EDL muscles from CASQ1-null mice ap-
pear more red-colored than EDL muscles from WT mice
(see Additional file 6: Figure S3).
We also quantified the number of mitochondria exhi-
biting one or more of the following alterations: a) swell-
ing, b) presence of vacuoles, c) clear disruption of the
external membrane and/or internal cristae, and d) mye-
lin figures (see examples in Figure 6D,E,F). Although the
frequency of damaged mitochondria varied significantly
from fiber to fiber and from area to area, the percentage
was significantly (P < 0.01) increased in muscle fibers from
4- 6-month-old CASQ1-null mice compared to that of
age-matched WT mice (15.08% ± 0.9% vs. 2.65% ± 0.5%,
respectively; Figure 6G and Table 1). Interestingly,
PGC-1α expression is slightly down-regulated in CASQ1-
null muscle at 25 months of age (see Additional file 2:
Figure S2), suggesting that the replacement of damaged
mitochondria in the muscle of aged CASQ1-null mice
could be impaired, thus resulting in an accumulation of
damaged mitochondria.
As detailed above, muscle fibers from CASQ1-null mice
exhibited an age-dependent increase in the development
of structural cores (Figures 2, 3, 4 and Additional file 3:
Table S1). In order to correlate mitochondrial damage to
Figure 5 Age-dependant decrease in cross-sectional area (CSA) of EDL
fibers. Frequency distributions (A-C) and average CSA (D) of individual
EDL fibers at three different ages. Average fiber CSA is significantly
reduced in CASQ1-null mice compared to age-matched WT mice across
all age groups tested. Note that CSA of fibers decreases with age in both
genotypes (D), but the major reduction in fibers from CASQ1-null mice
occurs from 4 to 6 months to 14 months of age, whereas this reduction
occurs later in WT mice (that is, between 14 and 24 months). Data given
in μm2 are expressed as means ± SEM (**P< 0.01). EDL, extensor
digitorum brevis; CASQ1, skeletal isoform of calsequestrin; WT, wild type.
Paolini et al. Skeletal Muscle  (2015) 5:10 Page 9 of 17core formation, we measured the relative volume oc-
cupied by mitochondria in non-core and core regions
of aged (27 months old) CASQ1-null mice. In regions
of muscle fibers exhibiting only modest alterations
(similar-normal areas), mitochondrial volume was
increased in aged mice compared to young adult mice
(13.26% ± 0.86% vs. 8.21% ± 0.29% at 27 months and
4 to 6 months, respectively; Figure 6C), consistent
with the visual impression of increased mitochondrial
size with age (Figure 2A). Interestingly, mitochondrial
volume was significantly reduced (6.01% ± 0.52%, P <
0.01) within unstructured and contracture cores (areas
such as those in Figure 2B,C,D), consistent with loss
of mitochondria in core regions.
Increased oxidative stress and mSOF activity in muscle
from CASQ1-null mice
The delicate balance between the production of oxida-
tive species and antioxidant defense is severely compro-
mised in several pathological conditions [46]. Given
that mitochondria are a primary source of reactive oxy-
gen species (ROS) generation and mitochondrial num-
ber/volume are increased in muscle fibers of CASQ1-
null mice (Figure 6), we compared the overall redox
state (GSH and GSSG) and the temperature dependence
of quantal mitochondrial superoxide production
(termed mitochondrial superoxide flashes or mSOFs
[42,47]) in skeletal muscle from 4- to 6-month-old WT
and CASQ1-null mice (Figure 7). This age was chosen
for these analyses because it represents a time at which
mitochondrial changes have already occurred but is
prior to the development of unstructured and contrac-
tion cores. The GSH/GSSG ratio was significantly (P <
0.01) reduced in EDL muscle homogenates from CASQ1-
null mice compared to that of WT mice (Figure 7A), con-
sistent with increased levels of oxidative stress in muscle of
CASQ1-null mice. Second, we determined the frequency
and amplitude (Figure 7B,C) of transient bursts of mito-
chondrial superoxide production that occur simultaneously
with mitochondrial depolarization in quiescent FDB fibers
from 4- to 5-month-old WT (Figure 7D,E,F) and CASQ1-
null mice (Figure 7G,H,I). Whereas no significant differ-
ences in mSOF frequency or amplitude were detected at
room temperature (20°C), a significant (P < 0.05) increase
in mSOF frequency was observed at physiological
temperature (37°C) in FDB fibers from CASQ1-null mice
(17.7 ± 1.3 and 25.7 ± 1.3 flashes/1,000 μm2∙100 s at 20°C
and 37°C, respectively) (Figure 7B,C). This temperature-
dependent increase was not observed in FDB fibers from
WT mice: 17.1 ± 1.1 and 19.2 ± 1.2 flashes/1,000 μm2∙100 s
at 20°C and 37°C, respectively. Importantly, the significant
(P < 0.05) increase in both mSOF frequency (Figure 7B)
and amplitude (Figure 7C) at 37°C in fibers from CASQ1-
null mice is consistent with the increased oxidative stress
Figure 6 Increased mitochondrial volume and mitochondrial damage in EDL muscles from 4- to 6-month-old CASQ1-null mice. (A, B) Representative
EM images showing increased mitochondrial number (empty arrows) in fibers from 4- to 6-month-old CASQ1-null mice (B) compared to WT mice
(A) (see also ref. [25]). (C) Frequency distribution of the relative percentage of fiber volume occupied by mitochondria in WT and CASQ1-null fibers.
Average (±SEM) percent mitochondrial volume is shown above each distribution (P < 0.01). (D-G) Representative mitochondria presenting structural
abnormalities (D-F), which are more frequent in fibers from CASQ1-null mice compared to that of WT mice (G). Number of WT and CASQ1-null animals
tested: n = 3. Number of fibers analyzed: n = 5. Data given as percentage ± SEM (**P < 0.01). Scale bars, (A, B): 0.2 μm; (D, E) and (G): 0.1 μm.EDL,
extensor digitorum brevis; EM, electron microscopy CASQ1, skeletal isoform of calsequestrin; WT, wild type.
Table 1 Percentage of mitochondria exhibiting different types of structural abnormalities in WT and CASQ1-null animals









WT 1.45 0.80 0.24 0.16 2.65 ± 0.5
CASQ1-null 6.22** 5.66** 1.96** 1.23** 15.08 ± 0.9**
In EDL muscles from 4- to 6-month-old mice, the percentage of mitochondria exhibiting one or more types of structural abnormality (swollen, disrupted internal
cristae, vacuoles, or myelin figures) is significantly increased in CASQ1-null mice. Data are means ± SEM (**P < 0.01). CASQ1, skeletal isoform of calsequestrin;
WT, wild type.
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Figure 7 Increased oxidative stress and temperature-dependent mSOF production in muscle from CASQ1-null mice. (A) Compared to WT
mice, muscle samples from CASQ1-null mice exhibit reduced GSH/GSSG ratio (A) (n = 6 per group). (B, C) Mean (±SEM n = 16 to 54 fibers)
mSOF frequency (B) and amplitude (C) at 20°C and 37°C for FDB fibers. (D) Representative mt-cpYFP confocal image of an FDB fiber at 37°C
from a WT mouse; boxed region indicates an area containing a mSOF. (E) Top: series of pseudocolor time-lapse images from the boxed
region in (D); bottom, time course of mt-cpYFP (green) and TMRE (red) fluorescence for the event indicated in (D). (F) Output standard
deviation map (100 images, 1.2 s/frame) of mSOF activity for the WT FDB fiber shown in (E). Events are circled in magenta. (G-I) Same as
(D-F) except for a FDB fiber at 37°C from a CASQ1-null mouse. (J) Representative mSOF event registry over time for the WT fiber (left) and the
CASQ1-null fiber (right). Flash frequency (Ff) is indicated to the right of the corresponding registry trace. Data expressed as mean ± SEM.
(*P < 0.05). Scale bars: (D, F, G, and I), 10 μm. CASQ1, skeletal isoform of calsequestrin; GSH/GSSG, reduced and oxidized glutathione; mSOF,
mitochondrial superoxide flashes; mt-cpYFP, mitochondria-targeted circularly permuted yellow fluorescent protein; TMRE, tetramethylrhodamine ethyl
ester; WT, wild type.
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mice (Figure 7A). As elevated levels of ROS can dam-
age critical cellular components including proteins
and membrane lipids [48], these results may explain
the increased mitochondrial damage observed in
muscle fibers from 4- to 6-month-old CASQ1-null
mice (Figure 6G).NAC treatment of CASQ1-null mice reduces oxidative stress
and mSOF production, prevents mitochondrial volume/
damage, and improves muscle function
To determine if excessive oxidative stress in CASQ1-null
mice is responsible for mitochondrial alterations (Figure 6),
muscle damage (Figures 2, 3, and 4), and reduced con-
tractility (Figure 1), mice were provided NAC (a potent
Paolini et al. Skeletal Muscle  (2015) 5:10 Page 12 of 17anti-oxidant and precursor for glutathione synthesis) in
their drinking water for 2 months (that is, from 2 to 4
months of age). Long-term NAC treatment in-vivo nor-
malized muscle GSH/GSSG to control levels (Figure 8A;
P < 0.05). In addition, acute in-vitro treatment of isolated
FDB fibers with 2.5 mM NAC for 30 min reduced mSOF
frequency at 20°C and 37°C in both WT and CASQ1-null
mice. Specifically, NAC treatment normalized mSOF
frequency at 37°C in fibers from CASQ1-null mice to a
level not different to that of fibers from WT mice in the
absence of NAC treatment (Figure 8B, dash line; P <
0.05). No change in mSOF amplitude was detected (see
Additional file 7: Figure S4). Together, results in Figure 8A,B
indicate that NAC treatment restored the oxidative
balance muscle from CASQ1-null mice. Importantly,
long-term NAC treatment of CASQ1-null mice mark-
edly reduced structural alterations typically observedFigure 8 N-acetylcysteine (NAC) reduces oxidative stress, mSOF production
(A) GSH/GSSG ratio was restored to normal levels in muscle homogenates
group). (B) Acute NAC treatment in FDB fibers reduced mSOF frequency at
months reduced total mitochondrial volume (C) and mitochondrial damag
NAC treatment) and of old CASQ1-null animals tested: n = 3. Number of fib
treatment) tested: n = 3. Number of analyzed fibers: n = 5. Data expressed a
calsequestrin; GSH/GSSG, reduced and oxidized glutathione; FDB, flexor digat 4 months of age, including increased mitochondrial
volume (Figure 8C; P < 0.05 and P < 0.01) and mito-
chondria damage (Figure 8D; P < 0.01). Finally, NAC
treatment also partially rescued overall neuromuscular
function, as shown by a significant improvement in
grip strength (Figure 8E; P < 0.01).Discussion
In humans, CCD and MHS are related disorders as some
patients with CCD also test positive for MHS [10,16].
Thus, individuals with CCD are typically considered at
risk for an MH episode during anesthesia using triggering
agents (for example, halothane). In this regard, we previ-
ously reported that CASQ1-null mice are susceptible to
lethal halothane- and heat-induced hypermetabolic epi-
sodes [29,31], a phenotype that closely resembles MHS in, and mitochondrial volume/damage and improves muscle function.
from CASQ1-null mice treated for 2 months with NAC (n = 6 per
both 20°C and 37°C. (C-E) NAC treatment of CASQ1-null mice for 2
e (D) and improved grip strength (E). Number of WT animals (without
ers analyzed: n = 5. Number of adult CASQ1-null animals (after NAC
s mean ± SEM (*P < 0.05 and **P < 0.01). CASQ1, skeletal isoform of
itorum brevis; mSOF, mitochondrial superoxide flashes; WT, wild type.
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tations [36,49].
The results presented in this study reinforce the con-
cept that the pathophysiology of MH and CCD share a
common underlying mechanism. Specifically, we dem-
onstrate that CASQ1-null mice develop a myopathy
characterized by mitochondrial damage at early ages that
precede the development of structural and contracture
cores at later ages (Figures 2, 3, and 4 and Additional file 3:
Table S1). Similar alterations were described previously in
biopsies from patients diagnosed with CCD and in RYR1
knock-in mouse models of core myopathy [35,50]. We
also investigated the mechanisms that contribute to the
mitochondrial damage observed in CASQ1-null mice and
identified excessive production of ROS as a key early event
in the myopathic cascade (possibly due to increased mito-
chondrial content and damage, see the ‘CASQ1-null
muscle shift toward a more oxidative phenotype’ section
below), confirming previous findings in a different mouse
model of CCD [35,49]. The common molecular mechan-
ism in these mouse models could be excessive SR leak
(see the ‘Proposed pathogenic mechanism for mitochon-
drial damage and myopathy in CASQ1-null mice’ section
below), resulting either directly by the mutations in the SR
Ca2+ release channel (in RYR1Y522S/WT knock-in mice)
[36,49] or indirectly by the loss of CASQ1-mediated in-
hibition of RYR1 channel activity in CASQ1-null mice
[29,31]. Importantly, we demonstrated a central role for
increased oxidative stress in the mitochondrial damage
and myopathy by rescuing multiple phenotypes in
CASQ1-null mice with anti-oxidant treatment (Figure 8).
Whereas oxidative stress, mitochondrial damage, or core
formation may definitely contribute to reduce muscle
strength reported in Figure 1, we cannot rule out the pos-
sibility that the impaired force output observed in
CASQ1 KO muscle is still primarily due to the altered SR
Ca2+ buffer and content and reduced Ca2+ release from
RYRs [25-28].
CASQ1-null muscle shift toward a more oxidative
phenotype
Whereas fiber-type switching (that is, change of myosin
isoform expression) does not occur in CASQ1-null mice
[25], the increase in mitochondrial number [25] and vol-
ume (Figure 6) in EDL muscle of CASQ1-null mice is
consistent with a shift toward increased oxidative me-
tabolism. Consistent with this, EDL muscles from
CASQ1-null mice are more red-colored than those from
age-matched WT mice (Additional file 6: Figure S3).
The increased mitochondrial density observed in EDL
muscle fibers (Figure 6; [18]) may be due to the ob-
served increased in PGC-1α expression (Additional file 2:
Figure S2), a transcriptional co-activator that stimulates
mitochondrial biogenesis and promotes the remodeling ofmuscle tissue toward increased oxidative metabolism
[45,51]. The exact molecular signals linking CASQ1 defi-
ciency to an up-regulation of PGC-1α remain unclear and,
thus, are worthy of further investigation. However, in-
creases in cytoplasmic Ca2+ and metabolic demand, as
well as ATP deficiency, are all known to enhance PGC-1α
expression [52-54]. Thus, since free myoplasmic Ca2+ levels
are increased at physiological temperature in CASQ1-null
fibers [29], a Ca2+-mediated increase in PGC-1α expres-
sion could underlie the up-regulation of this signaling
pathway.
Increased oxidative stress in CASQ1-null mice
A significant fraction of mitochondria in muscle from
CASQ1-null mice exhibit morphological abnormalities
(Figures 2 and 6). This increased structural damage of
mitochondria (Figure 6) could result from the combined
effects of elevated myoplasmic Ca2+ [29] and redox im-
balance. Indeed, mitochondria, which are located in
proximity of CRUs [25,55], are in a position to be dir-
ectly impacted by Ca2+ disturbances at adjacent CRUs
that lack CASQ1. In addition, the decrease in GSH/
GSSG ratio and increase in mSOF activity (Figure 7) in
muscle from CASQ1-null mice are indicative of in-
creased mitochondrial-derived oxidative stress. Mito-
chondria, which produce superoxide as a byproduct of
oxygen consumption due to electron slippage from the
electron transport chain during aerobic respiration [56],
are a primary source of ROS production within the cell.
However, our results do not preclude a potential role of
additional ROS sources, including NADPH oxidase [57],
to the increased oxidative stress observed in muscle
from CASQ1-null mice. Nevertheless, the increase in
mitochondrial number/volume (Figure 6) [29] and en-
hanced mitochondrial superoxide production (Figure 7)
likely contribute to the augmented oxidative stress ob-
served in muscle from CASQ1-null mice (Figure 7A).
These changes could in turn lead to oxidative modifica-
tions/damage to critical cellular proteins, membrane
lipids, and various organelles, including mitochondria
[48]. Furthermore, damaged mitochondria may not func-
tion properly and, thus, produce additional ROS, driving
a dangerous feed-forward mechanism that further exac-
erbates cellular damage. This vicious cycle resembles
that described previously in a mouse model of MH with
cores (RYR1Y522S/WT mice), which also exhibits a marked
temperature-dependent increase in resting myoplasmic
Ca2+, oxidative stress [49], and mSOF activity [42].
Rescue by NAC treatment suggests a central role of
oxidative stress in the myopathic cascade
Enhanced oxidative stress plays a critical role in both MH
susceptibility [36,49] and the formation of cores that lack
mitochondria in RYR1Y522S/WT mice [35]. A similar
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drial damage and muscle dysfunction observed in
CASQ1-null mice is supported by data presented in
Figure 8. These studies demonstrate that treatment of
CASQ1-null mice with a potent anti-oxidant (NAC) for 2
months restored the muscle redox state, reduced mito-
chondrial alterations, and improved muscle functionality
(Figure 8). By analogy to that observed for RYR1Y522S/WT
mice [49], we speculate that a reduction of oxidative stress
in CASQ1-null mice may reduce S-nitrosylation of RYR1
to block the deleterious feed-forward cycle of increased
SR Ca2+ leak and ROS production. However, future exper-
iments are needed to demonstrate a critical role for RYR1
S-nitrosylation in the mitochondrial proliferation, damage,
and core myopathy observed in CASQ1-null mice.Proposed pathogenic mechanism for mitochondrial
damage and myopathy in CASQ1-null mice
The schematic in Figure 9 summarizes a proposed se-
quence of events that leads to mitochondrial prolifera-
tion, increased oxidative stress, and mitochondrial
damage and, over time, the development of a core-like
myopathy in CASQ1-null mice. Dainese et al. [29] re-
ported that muscle fibers from CASQ1-null mice ex-
hibit high-resting Ca2+ levels at body temperature.
This excess in intracellular Ca2+ may result from en-
hanced SR Ca2+ leak (possibly due to loss of CASQ1-
mediated RYR1 inhibition) and/or excessive store de-
pletion leading to store-operated Ca2+ entry (SOCE)
from the extracellular space (step 1). Both effects are
supported by existing literature: a) CASQ1 inhibits
RYR1-opening probability and Ca2+ release [23,29], b)
CASQ1-deficiency results in a temperature-dependent
increase in resting free myoplasmic Ca2+ [58], and c)
SOCE activation is increased in myotubes from
CASQ1-null mice [58,59]. Indeed, enhanced SOCE
could result from the greater susceptibility for activity-
dependent SR Ca2+ depletion previously demonstrated
in muscle fibers from CASQ1-null mice [25,27,28]. En-
hanced resting Ca2+ levels would also increase ATP hy-
drolysis/demand required for SERCA-mediated SR Ca2
+ reuptake (step 2), which together would increase
PGC-1α expression [53,54] that promotes mitochon-
drial biogenesis and oxidative energy production (step
3). The ensuing increase in aerobic metabolism would lead
to increased mitochondrial superoxide production (lower-
ing GSH/GSSG ratio), which in turn would increase oxi-
dative stress that further challenges mitochondrial
integrity (steps 4 and 5) that promotes the formation of
myopathic core-like regions (steps 6). Recent work sup-
ports a pivotal role for oxidative stress in altering the bal-
ance between protein synthesis and degradation in
unloading and disuse atrophy [46].Differences between structural modifications in muscle in
CASQ1-null mice and those described in biopsies from
patients carrying the p.Asp244Gly disease mutation in
CASQ1
The first mutation in the CASQ1 gene linked to human
disease was recently reported [34]. In this report, a dom-
inant missense mutation in CASQ1 (N244G) was found
in a group of patients with a vacuolar myopathy charac-
terized by weakness, fatigue, and the presence of
electron-dense inclusions. The structural modifications
described in biopsies from these patients do not resem-
ble in any way the alterations (that is, unstructured and
contracture cores) described in CASQ1-null mice. How-
ever, the degree to which mitochondrial alterations are
observed in muscle biopsies from CASQ1 N244G vacu-
olar myopathy patients is currently unknown. Importantly,
large SR vacuoles containing electron-dense material,
which likely reflects abnormal CASQ1 aggregation, are
observed in patients with the N244G CASQ1 mutation.
These alterations closely resemble those described previ-
ously in skeletal muscle fibers and cardiac myocytes from
mice that overexpress CASQ1 and CASQ2 [60,61]. On
the other hand, in muscle fibers from CASQ1-null mice,
the SR is not swollen (but is actually reduced in size),
CRUs form multiple junctions with T-tubules, and the ter-
minal cisternae of the SR lacks electron dense material
(that is, CASQ1) [25].
Conclusions
There are currently no curative treatments for CCD
patients. Thus, a deeper mechanistic understanding of
the molecular mechanisms that underlie mitochondrial
damage and the formation of cores in CCD is needed in
order to identify potential new therapeutic targets and,
thus, to develop effective new interventions for this dis-
order. The mechanisms responsible for the loss of mito-
chondrial activity in core regions of muscle from CCD
patients have also not yet been elucidated. Especially
challenging is to explain how both gain- and loss-of-
function mutations in RYR1 lead to myopathies charac-
terized by damage and destruction of mitochondria (that
is, CCD and multi-minicore disease), formation of struc-
tural and contracture cores, and muscle weakness.
Mutations in the CASQ1 gene have not been iden-
tified in patients diagnosed with either CCD or in
MHS [32], and this represents a clear limit of our
mouse model. Nevertheless, data of our study show
that CASQ1 deficiency results in an age-dependent
myopathy characterized by mitochondrial damage
and formation of unstructured/contracture cores re-
sembling those described in muscle biopsies from hu-
man CCD patients and in other mouse models of
MH and CCD (see ref. [35,50]). In addition, we
found that the molecular mechanisms observed in
Figure 9 Proposed pathogenic model for myopathy in CASQ1-null mice. 1) CASQ1-null fibers exhibit elevated resting Ca2+ levels at body
temperature [29], likely caused by increased RYR1 Ca2+ leak and/or enhanced SOCE [58,59]. 2) High cytoplasmic-resting Ca2+ increases the
demand for ATP required to drive SERCA-mediated SR Ca2+ reuptake. 3) Increases in Ca2+ and energy demand enhance PGC-1α expression and,
thus, mitochondrial biogenesis. 4-5) Increased metabolic rate and mitochondrial content enhance mSOF production and oxidative stress, which,
over time, leads to mitochondrial damage. 6) Chronic exposure of fibers to high Ca2+ and oxidative stress results in formation of core-like regions
(that is, myopathy). The central role of enhanced oxidative stress as a requisite step in this pathogenic model is supported by the demonstration
that NAC treatment reduces mitochondrial damage and improves muscle function. Ca2+, calcium ions; CASQ1, skeletal isoform of calsequestrin;
SR, sarcoplasmic reticulum; GSH/GSSG, reduced and oxidized glutathione; mSOF, mitochondrial superoxide flashes; PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha; RYR1, ryanodine receptor type-1; SOCE, store-operated Ca2+ entry; WT, wild type;
NAC, N-acetylcysteine.
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dative stress, mitochondrial damage) parallel those
reported previously in a knock-in mouse carrying a
human mutation [35].
We propose that increased oxidative stress (Figure 7),
likely resulting from an imbalance of intracellular Ca2+
homeostasis [25,26,28-30], is a critical early myopathic
trigger in CASQ1-null mice. In support of this hypoth-
esis, we show that treatment with NAC, a potent anti-
oxidant, corrected the increased oxidative stress,
reduced the incidence of mitochondrial damage, and im-
proved muscle function of CASQ1-null mice (Figure 8).
These results suggest that NAC (or other anti-oxidants,[42,47]) could be considered as a therapeutic inter-
vention to prevent mitochondrial damage and im-
prove muscle function in CCD and, more generally,
to mitigate the deleterious effects of increased oxida-
tive stress and mitochondrial damage in other muscle
disorders [62].Additional files
Additional file 1: Figure S1. Age-dependent survival curve. This is a
figure showing the mortality rate of male and female WT and CASQ1-null
mice. Detailed description is provided within the file.
Paolini et al. Skeletal Muscle  (2015) 5:10 Page 16 of 17Additional file 2: Figure S2. PGC-1α expression. This is a figure showing
representative Western blot of PGC-1α of EDL total homogenates at 4 and
25 months of age. Detailed description is provided within the file.
Additional file 3: Table S1. Analysis of structural disarray. Detailed
description is provided within the file.
Additional file 4: Table S2. Body and muscle weight. Detailed
description is provided within the file.
Additional file 5: Table S3. Gene microarray analysis. Detailed
description is provided within the file.
Additional file 6: Figure S3. Dissected EDL muscles. This is a figure
showing the color of EDL muscles from WT and CASQ1-null mice. Detailed
description is provided within the file.
Additional file 7: Figure S4. Mitochondrial superoxide flashes. This is a
figure showing the temperature dependence of mitochondrial
superoxide flash activity in the presence or absence of NAC. Detailed
description is provided within the file.
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